The company said over 10 emerging markets along with Japan, Australia and New Zealand have transitioned in this final phase of the integration of the biosimilars business acquired from Viatris. With the completion of this significant milestone, Biocon Biologics is now a fully integrated ‘lab to market biosimilars company committed to serving millions of patients across the globe.
Biocon Biologics personnel working at the insulin devices manufacturing facility in Bengaluru, India. Biocon Biologics personnel working at the insulin devices manufacturing facility in Bengaluru, India. BENGALURU, India, Nov. 30, 2023 (GLOBE NEWSWIRE) Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris’ biosimilars business in 31 European countries has been successfully completed. Following the acquisitio
Viatris is the old generic drug company Mylan, acquired by Pfizer and merged with its Upjohn division. The stock has been falling ever since the deal closed.